Shionogi and F2G’s invasive aspergillosis drug shows long-term benefit

Patients treated with Shionogi & F2G’s invasive aspergillosis drug were released from hospital sooner than those in the comparator arm. Patients treated with Shionogi & F2G’s invasive aspergillosis drug were released from hospital sooner than those in the comparator arm. The drug was previously refused for approval by the FDA. Credit: SeventyFour / Shutterstock.com Shionogi and F2G are releasing further data from a non-inferiority study of the latter’s oral invasive aspergillosis drug, showing its promise in longer-term mortality. In the Phase III OASIS trial (NCT05101187) evaluating oral olorofim for the fungal infection, similar efficacy was seen across secondary endpoints, as…

Source: Clinical Trials Arena